Sodium Bicarbonate for Critically Ill Patients With Metabolic Acidosis and Acute Kidney Injury

The study investigates whether sodium bicarbonate is able to reduce the occurrence of major adverse kidney events on day 90 (MAKE90) in critically ill patients with metabolic acidosis and acute kidney injury (AKI). While its efficacy in this context has been suggested in a subgroup analysis of the BICAR-ICU trial it has not been confirmed in a double-blinded randomized controlled trial to date.

NCT Number	NCT07464431
Lead Sponsor	Universität Münster Collaborators: German Research Foundation
Conditions	Acute Kidney Injury, Metabolic Acidosis, Critical Illness
Enrollment	660 participants
Start Date	2026-05
Primary Completion	2028-06 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-05